Agrawal L, …



CLINICIAN TOOLKITSCCHN BackgroundResourceAddressAgrawal L, Bacal A, Jain S, et al. Immune checkpoint inhibitors and endocrine side effects, a narrative review. Postgrad Med. 2020;132:206-214. doi:10.1080/00325481.2019.1709344 Cancer Society. About Oral Cavity and Oropharyngeal Cancer. Published 2018. Cancer Society. Oral Cavity and Oropharyngeal Cancer Causes, Risk Factors, and Prevention. Published 2020. A, Li S, Ghebremichael M, et al. Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. Ann Oncol. 2014;25:1410-1416. doi:10.1093/annonc/mdu167 for Disease Control and Prevention. HPV-Associated Oropharyngeal Cancer Rates by Race and Ethnicity. Published August 2019. AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294-4301. doi:10.1200/JCO.2011.36.4596 S, Ganguly K, Muniyan S, et al. Immunometabolic alterations by HPV infection: New dimensions to head and neck cancer disparity. J Natl Cancer Inst. 2019;111:233-244. doi:10.1093/jnci/djy207, RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol. 2015;33:3293-3304. M, Pravin J, Rodrigues L, et al. CD137/OX40 bispecific antibody induces potent antitumor activity that is dependent on target coengagement. Cancer Immunol Res. 2020;8:781-793. doi:10.1158/2326-6066.CIR-19-0798 DN, Van Waes C, Seiwert TY. Genetic landscape of human papillomavirus-associated head and neck cancer and comparison to tobacco-related tumors. J Clin Oncol. 2015;33:3227-3234. doi:10.1200/JCO.2015.62.1086 K, Amonkar MM, H?gberg D, Kasteng F. Economic burden of resected squamous cell carcinoma of the head and neck in an incident cohort of patients in the UK. Head Neck Oncol. 2011;3:47. doi:10.1186/1758-3284-3-47. Cancer Institute. Head and Neck Cancers Fact Sheet. Published 2017. Cancer Institute. Cancer Causes and Prevention. HPV and Cancer. Published 2020. Cancer Institute. Oral Cavity, Pharyngeal, and Laryngeal Cancer Prevention (PDQ?)–Health Professional Version. Published 2020. RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7-30. doi:10.3322/caac.21590 for International Cancer Control. Head and Neck Cancer - Review of Cancer Medicines on the WHO List of Essential Medicines. 2014. DataResourceAddressBurtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [published correction appears in Lancet. 2020;395:272] [published correction appears in Lancet. 2020;395:564]. Lancet. 2019;394:1915-1928. doi:10.1016/S0140-6736(19)32591-7 LQM, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016;34:3838-3845. doi:10.1200/JCO.2016.68.1478 RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856-1867. doi:10.1056/NEJMoa1602252 RL, Blumenschein G Jr, Fayette J, et al. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018;81:45-51. doi:10.1016/j.oraloncology.2018.04.008.. Anti-hPD1-Pem-hIgG2. Published January 29, 2020. Accessed June 24, 2020.. Anti-hPD1-Ni-hIgG4 (S228P). Published May 24, 2020. O, Galluzzi L, Martins I, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev. 2011;30:61-69. doi:10.1007/s10555-011-9273-4 LF, Haddad RI, Even C, et al. EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol. 2019;37(15_suppl):6012. doi:10.1200/jco.2019.37.15_suppl.6012 (Opdivo) [Package Insert]. Bristol-Myers Squibb Company, Princeton, NJ. June 2020 (Keytruda) [Package Insert]. Merck & Co., Inc., Whitehouse Station, NJ. June 2020. D, Harrington KJ, Greil R, et al. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol. 2019;37(15_suppl):6000. doi:10.1200/jco.2019.37.15_suppl.6000 TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956-965. doi:10.1016/S1470-2045(16)30066-3. Food and Drug Administration. FDA approves pembrolizumab for first-line treatment of head and necks. Published June 11, 2019. Adverse Events in SCCHNResourceAddressBrahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-1768. doi:10.1200/JCO.2017.77.6385 DJ, Baugh CW, Postow MA, Caterino JM, Erickson TB, Lyman GH. Immune-related adverse events in cancer patients. Acad Emerg Med. 2018;25:819-827. doi:10.1111/acem.13443 MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158-168. doi:10.1056/NEJMra1703481 Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5:95. 2017;5:95 doi:10.1186/s40425-017-0300-z M, Ferrucci PF, Hogg D, et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol. 2017;35:3815-3822. doi:10.1200/JCO.2016.72.1167 JS, K?hler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691-2697. doi:10.1200/JCO.2012.41.6750 to Clinical TrialsTrialAddressEA3161NCT03811015 JAVELINNCT02952586 MK-3475-689NCT03765918 PATHWayNCT02841748 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download